Report on short-term side effects of treatments with (177)Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours

PURPOSE: Treatment with the radiolabelled somatostatin analogue (177)Lu-octreotate results in tumour remission in 47% of patients with gastroenteropancreatic neuroendocrine tumours. Adding capecitabine to (177)Lu-octreotate, as a radio-sensitiser, may enhance these anti-tumour effects. We now presen...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: van Essen, Martijn, Krenning, Eric P., Kam, Boen L., de Herder, Wouter W., van Aken, Maarten O., Kwekkeboom, Dik J.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2008
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2668587/
https://ncbi.nlm.nih.gov/pubmed/18188559
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00259-007-0688-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados